Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, small cell
Stage/Subtype:  recurrent small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 33 for your search:
Start Over
Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-331, NCI-2015-01362, 2015-001097-18, NCT02481830
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Olaparib and Temozolomide in Treating Patients with Recurrent Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-121, NCI-2015-01724, NCT02446704
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA212-115, NCI-2015-01260, 2015-000136-15, NCT02472977
Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-03, NCI-2015-01365, NCT02514447
ATR Kinase Inhibitor VX-970 and Topotecan Hydrochloride in Treating Patients with Previously Treated Lung, Ovarian, Cervical, or Neuroendocrine Cancers
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0150, NCI-2015-01398, 346215, P142115, NCT02487095
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Stereotactic Body Radiation Therapy, Radiofrequency Ablation, and Microwave Ablation in Treating Patients with Inoperable and Recurrent Lung Cancer Near Central Airways
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-08-026, NCI-2010-01669, 10-000656, JCCC-SUPPL-3, NCT01051037
Targeted Enzyme Inhibitor Therapy in Treating Patients with Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, 8639, NCT01306045
Cabozantinib-s-malate in Treating Patients with Metastatic or Refractory Solid Tumors and Bone Metastases
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-091, NCI-2012-00991, NCT01588821
Pegylated Irinotecan NKTR 102 in Treating Patients with Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 225612, NCI-2013-01142, NCT01876446
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ALDOXORUBICIN-P2-SCLC-01, NCI-2014-02472, NCT02200757
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, 350, 351, NCT02312622
Selinexor in Treating Patients with Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14136, NCI-2014-02489, NCT02351505
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 2015-002067-41, NCT02628067
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 508-08, NCI-2009-01308, UNMC-50808, IRB #508-08, NCT00856037
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Belinostat, Cisplatin, and Etoposide in Treating Patients with Recurrent or Advanced Small Cell Lung Cancer or Neuroendocrine Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0173, NCI-2013-01451, 090173, 09-25-0099, NCI 8238, P09511, 8238, NCT00926640
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 200858, NCI-2014-00693, NCT02034123
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNX5422-CLN-009, NCI-2014-02577, NCT02063958
Start Over